The global digital biomanufacturing market is rapidly evolving as biopharmaceutical companies increasingly adopt advanced digital technologies to improve production efficiency, quality, scalability, and operational flexibility. Valued at US$ 21.1 Bn in 2024, the market is projected to expand at a CAGR of 9.2% from 2025 to 2035, surpassing US$ 55.6 Bn by 2035.

Rising Demand for Biologics Accelerates Market Growth

The growing demand for monoclonal antibodies, vaccines, and cell and gene therapies is a major factor driving digital biomanufacturing adoption. As biologic therapies become increasingly important for treating cancer, autoimmune disorders, chronic diseases, and other complex conditions, manufacturers face growing pressure to increase production while maintaining consistent quality.

Digital technologies help address these challenges by enabling real-time process monitoring, automated decision-making, predictive analytics, and improved resource utilization. Manufacturing execution systems (MES), process analytical technology (PAT), and advanced data analytics allow manufacturers to identify deviations quickly and optimize processes throughout the production cycle.

The shift toward personalized medicine is also creating demand for flexible manufacturing systems capable of adapting to changing production requirements. Digital biomanufacturing enables greater responsiveness and supports the development of scalable manufacturing models for increasingly complex therapies.

AI, IoT, and Digital Twins Reshape Biomanufacturing

Technological advancements are fundamentally changing conventional biomanufacturing processes. Artificial intelligence (AI) and machine learning can analyze large volumes of production data to identify patterns, predict potential problems, and optimize manufacturing parameters.

Meanwhile, the Internet of Things (IoT) enables connected equipment and sensors to continuously collect and transmit operational data. This improves visibility across manufacturing environments and reduces reliance on manual monitoring.

Digital twins are another emerging technology with significant potential. By creating virtual representations of physical processes or systems, digital twins allow manufacturers to simulate production scenarios before implementing changes in real-world operations. This can support risk management, process optimization, and better decision-making.

Get Sample PDF: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86631

MES Segment Leads the Market

The manufacturing execution system (MES) segment is expected to maintain a leading position in the digital biomanufacturing market. MES provides centralized monitoring and management of production, quality, and operational workflows, helping manufacturers establish a connected and data-driven manufacturing environment.

Process analytical technology (PAT) is also gaining importance by enabling real-time analysis of manufacturing processes. The combination of MES and PAT can help manufacturers detect deviations earlier, reduce waste, improve consistency, and strengthen regulatory compliance.

North America Holds a Leading Position

North America dominated the digital biomanufacturing market in 2024, supported by its established biopharmaceutical ecosystem, strong research infrastructure, technology providers, and significant investment in innovation.

The region's favorable regulatory environment and focus on advanced manufacturing technologies are encouraging companies to integrate AI, IoT, automation, and analytics into bioprocessing operations. Continued investment in biopharmaceutical R&D is expected to reinforce North America's position during the forecast period.

Competitive Landscape and Recent Developments

Leading companies operating in the market include Cytiva (Danaher Corporation), Eppendorf SE, Sartorius AG, Merck KGaA, Aspen Technology Inc., Körber AG, AmpleLogic, Siemens, Thermo Fisher Scientific Inc., ABB, Bruker, Hamilton Company, Dassault Systèmes, Kymanox Corporation, Invert, Inc., and Genedata AG.

Strategic collaborations are increasingly shaping the competitive landscape. In April 2025, Sartorius Stedim Biotech collaborated with Tulip Interfaces to accelerate digital transformation in biopharmaceutical manufacturing. In January 2025, Cytiva partnered with Cellular Origins to combine automated platforms for digitally connected cell therapy manufacturing.

Future Outlook

The future of digital biomanufacturing will be shaped by the convergence of AI, machine learning, IoT, automation, MES, PAT, data analytics, and digital twins. As manufacturers seek greater efficiency and flexibility while meeting stringent quality requirements, digital ecosystems are expected to become increasingly integral to biopharmaceutical production.

With rising biologics demand and continued technological innovation, the digital biomanufacturing market is positioned for sustained expansion, supporting more efficient manufacturing and accelerating the delivery of advanced therapies to patients worldwide.

Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453